Chemistry:Flunitrazolam
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C17H12FN5O2 |
| Molar mass | 337.307 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Flunitrazolam (FNTZ, Flunazolam) is a triazolobenzodiazepine (TBZD), which are benzodiazepine (BZD) derivatives, that has been sold online as a designer drug, and is a potent hypnotic and sedative drug similar to related compounds such as flunitrazepam, clonazolam and flubromazolam. It was first definitively identified and reported to the EMCDDA Early Warning System, by an analytical laboratory in Germany in October 2016,[1] and had not been described in the scientific or patent literature before this.[2] It is the triazole analogue of Flunitrazepam (Rohypnol). The addition of the triazole ring to the scaffold increases potency significantly, this is evident as flunitrazolam is reported anecdotally to be active in the microgram level. It is active at 0.1 mg.[3][4]
See also
References
- ↑ "Europol 2016 Annual Report on the implementation of Council Decision 2005/387/JHA". https://www.europol.europa.eu/sites/default/files/documents/tdan17001enn_pdfweb.pdf.
- ↑ "New benzodiazepines for sedation". Best Practice & Research. Clinical Anaesthesiology 32 (2): 149–164. June 2018. doi:10.1016/j.bpa.2018.06.007. PMID 30322456.
- ↑ "Characterization of Flunitrazolam, a New Designer Benzodiazepine, in Oral Fluid After a Controlled Single Administration". Journal of Analytical Toxicology 42 (6): e58–e60. July 2018. doi:10.1093/jat/bky012. PMID 29462316.
- ↑ "Detection of the designer benzodiazepine flunitrazolam in urine and preliminary data on its metabolism". Drug Testing and Analysis 11 (2): 223–229. February 2019. doi:10.1002/dta.2480. PMID 30109775.
 |  |
